Related Experiment Video For immunohistochemical markers
Updated: Jun 4, 2025
Preparation and Analysis of In Vitro Three Dimensional Breast Carcinoma Surrogates
Published on: May 9, 2016
Comparison of the Structural, Cytological and Biomarker Expression in Carcinoma in situ and Invasive Components in
Azar Naimi1, Niloufar Mohaghegh2
1Department of Pathology, School of Medicine Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Background & Objective:
Breast cancer is thought to arise from non-invasive breast lesions, such as atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). DCIS is considered a direct precursor of invasive carcinoma. The morphological features alone do not reflect the biological truth of this disease. Therefore, we investigated features of carcinoma in situ and the invasive components in women diagnosed with breast cancer.
Methods:
This study was a cross-sectional study. The corresponding IHC slides were selected from the pathology archive and examined by the pathologist. Fifty-one samples which showed both in situ and invasive components confirmed immunohistochemically, were included in the study.
Results:
In 70.6% of the cases a high grade of in situ and invasive carcinoma was observed. In 45.1% of the studied cases, a solid structure was observed in in-situ carcinoma, and no otherwise specified structure was observed in invasive carcinoma. In 74.5% of both in situ and invasive carcinoma types, ER.PR had a positive value. In 45.5% of the cases, both in situ and invasive carcinoma components show low Ki67. In 42.2%, both in situ and invasive carcinomas were Her2 negative. There was no significant difference between the grade (P=0.687), Her2 type (P=0.532), and structure (P=0.532). ER.PR (P=1.00) and Ki67 (P=0.180) of in situ and invasive carcinoma in this study.
Conclusion:
Our study showed differences between in situ and invasive biomarker expression. According to our findings, owing to heterogeneity, in situ components can't be representative of invasive components for treatment choices.
